194 related articles for article (PubMed ID: 12789846)
21. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials.
Ashcroft DM; Dimmock P; Garside R; Stein K; Williams HC
BMJ; 2005 Mar; 330(7490):516. PubMed ID: 15731121
[TBL] [Abstract][Full Text] [Related]
22. Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice.
Lübbe J; Friedlander SF; Cribier B; Morren MA; García-Díez A; Gelmetti C; Hofmann H; Houwing RH; Kownacki S; Langley RG; Virtanen M; Wolff K; Wisseh S; McGeown C; Abrams B; Schneider D;
Am J Clin Dermatol; 2006; 7(2):121-31. PubMed ID: 16605292
[TBL] [Abstract][Full Text] [Related]
23. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug.
Kapp A; Papp K; Bingham A; Fölster-Holst R; Ortonne JP; Potter PC; Gulliver W; Paul C; Molloy S; Barbier N; Thurston M; de Prost Y;
J Allergy Clin Immunol; 2002 Aug; 110(2):277-84. PubMed ID: 12170269
[TBL] [Abstract][Full Text] [Related]
24. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis.
Kempers S; Boguniewicz M; Carter E; Jarratt M; Pariser D; Stewart D; Stiller M; Tschen E; Chon K; Wisseh S; Abrams B
J Am Acad Dermatol; 2004 Oct; 51(4):515-25. PubMed ID: 15389185
[TBL] [Abstract][Full Text] [Related]
25. Effects of pimecrolimus cream 1% in the treatment of patients with atopic dermatitis who demonstrate a clinical insensitivity to topical corticosteroids: a randomized, multicentre vehicle-controlled trial.
Leung DY; Hanifin JM; Pariser DM; Barber KA; Langley RG; Schlievert PM; Abrams B; Hultsch T
Br J Dermatol; 2009 Aug; 161(2):435-43. PubMed ID: 19416245
[TBL] [Abstract][Full Text] [Related]
26. Pimecrolimus: new preparation. Me-too: too many risks, not beneficial enough in atopic dermatitis.
Prescrire Int; 2004 Dec; 13(74):209-12. PubMed ID: 15599989
[TBL] [Abstract][Full Text] [Related]
27. [Viewpoint of the German Dermatologic Society (DDG) concerning the decision of the American Food and Drug Administration (FDA) on the use of pimecrolimus cream and tacrolimus ointment in the treatment of atopic dermatitis (neurodermatitis)].
Luger TA; Gollnick H
J Dtsch Dermatol Ges; 2005 Jun; 3(6):415-6. PubMed ID: 15892843
[No Abstract] [Full Text] [Related]
28. [Long term management of childhood atopic dermatitis with calcineurin inhibitors].
Thaçi D
Hautarzt; 2003 May; 54(5):418-23. PubMed ID: 12719861
[TBL] [Abstract][Full Text] [Related]
29. Steroid-sparing effect of pimecrolimus cream 1% in children with severe atopic dermatitis.
Zuberbier T; Heinzerling L; Bieber T; Schauer U; Klebs S; Bräutigam M
Dermatology; 2007; 215(4):325-30. PubMed ID: 17911991
[TBL] [Abstract][Full Text] [Related]
30. Pimecrolimus: a review of pre-clinical and clinical data.
Graham-Brown RA; Grassberger M
Int J Clin Pract; 2003 May; 57(4):319-27. PubMed ID: 12800465
[TBL] [Abstract][Full Text] [Related]
31. Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective. An open study.
Thaçi D; Steinmeyer K; Ebelin ME; Scott G; Kaufmann R
Dermatology; 2003; 207(1):37-42. PubMed ID: 12835546
[TBL] [Abstract][Full Text] [Related]
32. Adult patients with moderate atopic dermatitis: tacrolimus ointment versus pimecrolimus cream.
Abramovits W; Fleischer AB; Jaracz E; Breneman D
J Drugs Dermatol; 2008 Dec; 7(12):1153-8. PubMed ID: 19137769
[TBL] [Abstract][Full Text] [Related]
33. Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients.
Eichenfield LF; Thaci D; de Prost Y; Puig L; Paul C
Dermatology; 2007; 215 Suppl 1():3-17. PubMed ID: 18174689
[TBL] [Abstract][Full Text] [Related]
34. Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: results of a > 2000 patient study.
Ring J; Abraham A; de Cuyper C; Kim K; Langeland T; Parra V; Pigatto P; Reunala T; Szczepanski R; Möhrenschlager M; Bräutigam M; Rossi AB; Meents-Kopecky E; Schneider D
J Eur Acad Dermatol Venereol; 2008 Feb; 22(2):195-203. PubMed ID: 18211413
[TBL] [Abstract][Full Text] [Related]
35. Topical tacrolimus for atopic dermatitis.
Cury Martins J; Martins C; Aoki V; Gois AF; Ishii HA; da Silva EM
Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD009864. PubMed ID: 26132597
[TBL] [Abstract][Full Text] [Related]
36. Topical pimecrolimus: a review of its use in the management of pediatric atopic dermatitis.
Yang LP; Curran MP
Paediatr Drugs; 2009; 11(6):407-26. PubMed ID: 19877726
[TBL] [Abstract][Full Text] [Related]
37. Improvement in pruritus in children with atopic dermatitis using pimecrolimus cream 1%.
Fowler J; Johnson A; Chen M; Abrams K
Cutis; 2007 Jan; 79(1):65-72. PubMed ID: 17330625
[TBL] [Abstract][Full Text] [Related]
38. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study.
Papp KA; Werfel T; Fölster-Holst R; Ortonne JP; Potter PC; de Prost Y; Davidson MJ; Barbier N; Goertz HP; Paul C
J Am Acad Dermatol; 2005 Feb; 52(2):240-6. PubMed ID: 15692468
[TBL] [Abstract][Full Text] [Related]
39. Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis.
Langley RG; Eichenfield LF; Lucky AW; Boguniewicz M; Barbier N; Cherill R
Pediatr Dermatol; 2008; 25(3):301-7. PubMed ID: 18577032
[TBL] [Abstract][Full Text] [Related]
40. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials.
Chen SL; Yan J; Wang FS
J Dermatolog Treat; 2010 May; 21(3):144-56. PubMed ID: 20394490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
